Welcome to our dedicated page for Shockwave Medical news (Ticker: SWAV), a resource for investors and traders seeking the latest updates and insights on Shockwave Medical stock.
Shockwave Medical, Inc. (SWAV) pioneers transformative cardiovascular therapies using its proprietary intravascular lithotripsy technology. This dedicated news hub provides investors and medical professionals with essential updates on the company’s advancements in treating calcified arterial disease.
Access consolidated, up-to-date information on SWAV’s regulatory milestones, clinical trial outcomes, and strategic initiatives. Our repository includes verified press releases covering product approvals, partnership announcements, and financial performance reports, all critical for evaluating the company’s market position.
Key updates feature developments in lithoplasty systems for coronary/peripheral arteries and the Shockwave Reducer for refractory angina. Track progress in real-world clinical adoption and research validating the safety profile of these minimally invasive solutions.
Bookmark this page to stay informed about Shockwave Medical’s innovations reshaping interventional cardiology. Regularly updated with authoritative sources, it serves as your primary resource for objective, compliance-focused reporting on SWAV’s contributions to medical technology.
Shockwave Medical, Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $218.8 million, a 36% increase from the same period in 2023. The company's gross profit was $190.6 million, operating expenses rose by 48%, and net income improved to $55.3 million. Adjusted EBITDA increased by 19% to $68.5 million. Shockwave Medical's cash position stood at $1,029.2 million as of March 31, 2024. The company has withdrawn its full year 2024 guidance due to the proposed acquisition by Johnson & Johnson.
FAQ
What is the current stock price of Shockwave Medical (SWAV)?
What is the market cap of Shockwave Medical (SWAV)?
